Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancer - PubMed
6 hours ago
- #Immunotherapy
- #Survival Analysis
- #NSCLC
- Adjuvant immunotherapy (adj-IO) does not significantly impact disease-free survival (DFS) or overall survival (OS) in patients with stage II-IIIB NSCLC who underwent neoadjuvant immunotherapy and complete resection.
- After propensity score matching, 102 patients in both adj-IO and non-adj-IO groups showed similar DFS (HR: 1.11, P=0.705) and OS (HR: 0.47, P=0.070).
- Subgroup analyses based on pathological response, PD-L1 expression, or histology revealed no survival benefit from adjuvant immunotherapy.
- Adjuvant immunotherapy is not an independent prognostic factor for DFS (P=0.427) or OS (P=0.210) in this patient population.
- The study suggests adjuvant immunotherapy may be omitted in perioperative treatment for these NSCLC patients.